Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a long non-coding RNA transcript produced from a genomic region antisense to the ZBTB34 gene (zinc finger and BTB domain containing 34). It is not a protein-coding gene, nor is it recognized as a therapeutic target. No experimental data establish a molecular function, biological role, or involvement in disease for this antisense RNA. It is catalogued as a novel lncRNA, typical for transcripts annotated as "novel transcript" and "antisense to" known genes in reference genome databases. Current knowledge about its function, disease relevance, or potential as a drug target is lacking. The protein-coding gene ZBTB34 ("zinc finger and BTB domain containing 34") is a DNA-binding transcriptional repressor and has some association with cancer, but the antisense lncRNA (ENSG00000296351) is a distinct entity for which there are no known biological or therapeutic functions. The only established information is its genomic location and orientation relative to ZBTB34; there are no validated aliases, protein products, or experimental characterization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to ZBTB34 (ENSG00000296351).